Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00414466 · ClinicalTrials.gov registry record · Phase 2
A Safety and Effectiveness Study of Intraspinal Gabapentin (MDT2004) for the Treatment of Chronic Pain
A Phase 2 study, sponsored by MedtronicNeuro.
- Terminated
- Registry status
- Phase 2
- Development phase
- 254
- Enrollment target
NCT00414466 is a Phase 2 study that was terminated before completion, run by MedtronicNeuro. The registered enrollment target is 254 participants.
The verdict
NCT00414466, a Phase 2 study, was terminated before completion, sponsored by MedtronicNeuro.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 254 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and minimum effective dose of intraspinal gabapentin when delivered through an implanted drug infusion system.
Interventions
- DRUG Intraspinal Gabapentin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2006-12 |
| Est. Completion | 2010-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00414466
The ClinicalTrials.gov registry entry for NCT00414466 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 254 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedtronicNeuro, which has 51 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intraspinal Gabapentin is the first listed.
NCT00414466 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00414466 about?
NCT00414466 is a clinical study titled "A Safety and Effectiveness Study of Intraspinal Gabapentin (MDT2004) for the Treatment of Chronic Pain". The purpose of this study is to determine the safety and minimum effective dose of intraspinal gabapentin when delivered through an implanted drug infusion system.
What is the current status of trial NCT00414466?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 254 participants. The study started on 2006-12. Estimated completion is 2010-08.
What interventions are being tested in trial NCT00414466?
The interventions under investigation include: Intraspinal Gabapentin (DRUG).
Who is sponsoring clinical trial NCT00414466?
This trial is sponsored by MedtronicNeuro, which has 51 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.